OPHTHOTECH CORPORATION (NASDAQ:OPHT) Files An 8-K Regulation FD Disclosure
Item 9.01 and as Exhibit 99.3 an investor presentation posted to the Company’s website (the “Original Presentation”). The sole purpose of this amendment is to replace the Original Presentation with an updated copy of such presentation. Other than as set forth in Item 9.01 below, no other disclosure in the Original Filing is amended by this Form 8-K/A.

Item 9.01. Regulation FD.

On July 26, 2017, Ophthotech Corporation posted an updated investor presentation to its website at http://investors.ophthotech.com/events.cfm. A copy of the investor presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K/A and is incorporated herein by reference.

The information in this Form8-K/A (including Exhibit 99.3) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following Exhibit relating to Item 9.01 shall be deemed to be furnished, and not filed:

99.3 Ophthotech Corporation Investor Presentation dated July 2017

Ophthotech Corp. Exhibit
EX-99.3 2 exhibit99307262017a01.htm EXHIBIT 99.3 exhibit99307262017a01 1 NASDAQ: OPHT July 2017 Corporate Overview   2 Forward-looking statements Any statements in this presentation about Ophthotech’s future expectations,…
To view the full exhibit click here

About OPHTHOTECH CORPORATION (NASDAQ:OPHT)

Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.